AbbVie Sues HRSA in D.C. District Court Over 340B Patient Definition, Post-Chevron Doctrinal Weapon
Issue
AbbVie filed a 72-page complaint April 8 in U.S. District Court for the District of Columbia against HRSA, HHS, Secretary Kennedy, and HRSA Administrator Engels — targeting the 1996 'patient definition' guidance that allows 340B drugs to be dispensed to non-FQHC contract patients. Post-Chevron doctrinal weapon: AbbVie argues HRSA's interpretive guidance lacks force of law.
If successful, would dramatically narrow which patients qualify for 340B savings and gut FQHC contract pharmacy revenue. Joins the pending Maine District Court case (AHA + 4 safety-net hospitals, already vacated rebate model in Feb 2026).
Combined regulatory + litigation pressure on HRSA's 340B authority is the most concentrated industry challenge in program history.
Sources for this story
AxiosSources for your board packet
This story's source plus 4 related stories and their sources, ready to print for your team or board.
Free. Unlocking the packet subscribes you to Intel Brief. You'll be subscribed right away, with no confirmation email. Unsubscribe with one click in any issue. If you unsubscribed before, we won't re-add you. We never sell your email. You can open each source above without an email.
Part of
- 340B drug pricing
AbbVie v. HRSA and the patient definition
FQHC Talent. (2026, April 8). AbbVie Sues HRSA in D.C. District Court Over 340B Patient Definition, Post-Chevron Doctrinal Weapon. Source: Axios. Retrieved October 6, 2026, from https://www.fqhctalent.com/intel/abbvie-sues-hrsa-340b-patient-definition-april-2026
More in Risk & Compliance
Sep 29
HHS civil rights office says when states can use substance use records
Sep 25
CMS and 37 states pledge to judge Medicaid by health outcomes
Sep 24
Geiger Gibson review finds health centers expect a heavy work-rule frailty burden
Sep 24
CMS seeks input on Part D pharmacy contract terms, including 340B claims